Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07095309 | Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer(NeoART-M) | not yet recruiting | Phase 2 | 120 | Metanoic Health Ltd.INDUSTRY | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07097064 | Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers(RAIPANC) | not yet recruiting | Phase 2 | 160 | Institut du Cancer de Montpellier - Val d'AurelleOTHER |
| 1 |
| Jul 31, 2025 |
| clinicaltrials |
| NCT07078305 | Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment | not yet recruiting | Phase 2 | 134 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07046221 | Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery | not yet recruiting | Phase 2 | 60 | Fujian Cancer HospitalOTHER_GOV | 0 | Jul 20, 2025 | clinicaltrials |
| NCT07075419 | JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 0 | Jul 20, 2025 | clinicaltrials |
| NCT07071844 | BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients(BETWEEN) | not yet recruiting | Phase 2 | 162 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07064668 | Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study | not yet recruiting | Phase 2 | 300 | Tongji HospitalOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07062328 | A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC(HP-BTC-002) | not yet recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07059949 | Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer(Union-mRC) | not yet recruiting | Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jul 11, 2025 | clinicaltrials |
| NCT07059338 | Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer(HERBIC) | not yet recruiting | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT07053150 | A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors(CCGLC-018) | not yet recruiting | Phase 2 | 80 | Tongji HospitalOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07051785 | Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer(ARK) | not yet recruiting | Phase 2 | 68 | Liu HuangOTHER | 0 | Jul 4, 2025 | clinicaltrials |
| NCT07049185 | QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma(QICE-ESCC) | not yet recruiting | Phase 2 | 35 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 3, 2025 | clinicaltrials |
| NCT07050524 | Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial | not yet recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT07045805 | Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer | not yet recruiting | Phase 2 | 66 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Jul 1, 2025 | clinicaltrials |
| NCT04901741 | Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer(OPTIMUS) | not yet recruiting | Phase 2 | 60 | TME Pharma AGINDUSTRY | 0 | Jun 27, 2025 | clinicaltrials |
| NCT06057831 | PET/MRI in Rectal Cancer | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 0 | Jun 18, 2025 | clinicaltrials |
| NCT07021950 | AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 130 | Sun Yat-sen UniversityOTHER | 0 | Jun 15, 2025 | clinicaltrials |
| NCT06646445 | Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.(PREMICES) | not yet recruiting | Phase 2 | 60 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07019181 | Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma | not yet recruiting | Phase 2 | 26 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT07018063 | Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer(YOUNG-NEOS) | not yet recruiting | Phase 2 | 35 | zhoujingOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07007728 | Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis | not yet recruiting | Phase 2 | 54 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07009145 | QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC | not yet recruiting | Phase 2 | 22 | Qianfoshan HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07003815 | Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 62 | Tongji HospitalOTHER | 0 | Jun 4, 2025 | clinicaltrials |
| NCT07000305 | A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer(SUPβORT) | not yet recruiting | Phase 2 | 42 | Tao ZhangOTHER | 1 | Jun 2, 2025 | clinicaltrials |
| NCT06998771 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | not yet recruiting | Phase 2 | 153 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT06999252 | Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients | not yet recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06999512 | Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer(HPB70+) | not yet recruiting | Phase 2 / Phase 3 | 526 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06991491 | Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004) | not yet recruiting | Phase 2 | 29 | West China HospitalOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT06993025 | Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06984718 | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | not yet recruiting | Phase 2 | 120 | AkesoINDUSTRY | 0 | May 22, 2025 | clinicaltrials |
| NCT06980389 | Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC) | not yet recruiting | Phase 2 | 176 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06861894 | Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC | not yet recruiting | Phase 2 | 164 | Zhigang LiOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06965829 | The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC | not yet recruiting | Phase 2 | 40 | Shanghai Chest HospitalOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT06957977 | A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer | not yet recruiting | Phase 2 | 42 | Zhongguang Luo, MDOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06958484 | Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence | not yet recruiting | Phase 2 | 60 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT06959693 | A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC) | not yet recruiting | Phase 2 / Phase 3 | 590 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06944548 | Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Metastatic COLorectal Cancer(APACOL) | not yet recruiting | Phase 2 | 54 | Centre Georges Francois LeclercOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06759233 | Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer | not yet recruiting | Phase 2 | 15 | Zhongguang Luo, MDOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06942767 | Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | not yet recruiting | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06946849 | Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study(SED-RO-ICC) | not yet recruiting | Phase 2 | 76 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06942663 | Randomized Phase II Trial Evaluating DFS in The Absence of an Adjuvant Component of Perioperative Chemotherapy in Patients With Gastric Cancer(JAGC1) | not yet recruiting | Phase 2 | 228 | Nizhny Novgorod Regional Clinical Oncology CenterOTHER_GOV | 0 | Apr 24, 2025 | clinicaltrials |
| NCT06938503 | AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 22, 2025 | clinicaltrials |
| NCT06935175 | A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 53 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06919510 | A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT06919848 | Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06) | not yet recruiting | Phase 2 | 74 | Fudan UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06911086 | SH-LPS System in Preoperative Planning for Liver Resection | not yet recruiting | Phase 2 / Phase 3 | 100 | Zhejiang Cancer HospitalOTHER | 0 | Apr 4, 2025 | clinicaltrials |
| NCT06903871 | Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR) | not yet recruiting | Phase 2 | 190 | Hebei Medical University Fourth HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2025source: clinicaltrials